Skip to content

Medical emergency? What to do

Hybrid molecules show promise for exploring, treating Alzheimer's

3-RXPublished November 5, 20094 min read

Key points

  • One of the many mysteries of Alzheimer's disease is how protein-like snippets called amyloid-beta peptides, which clump together to form plaques in the brain, may cause cell death, leading to the disease's devastating symptoms of memory loss and other mental difficulties.
  • University of Michigan researchers have developed new molecular tools that can be used to investigate the process.
  • One way of studying the role of metals in the process is by sopping up the metal ions with molecules called chelators and then seeing what happens when the metal ions are out of the picture.
  • Lim and coworkers used a new strategy to develop "bi-functional" small molecules that not only grab metal ions, but also interact with amyloid-beta.

One of the many mysteries of Alzheimer's disease is how protein-like snippets called amyloid-beta peptides, which clump together to form plaques in the brain, may cause cell death, leading to the disease's devastating symptoms of memory loss and other mental difficulties.

In order to answer that key question and develop new approaches to preventing the damage, scientists must first understand how amyloid-beta forms the telltale clumps.

University of Michigan researchers have developed new molecular tools that can be used to investigate the process. The molecules also hold promise in Alzheimer's disease treatment. The research, led by assistant professor Mi Hee Lim, was published online this week in the Journal of the American Chemical Society.

Though the exact mechanism for amyloid-beta clump formation isn't known, scientists do know that copper and zinc ions are somehow involved, not only in the aggregation process, but apparently also in the resulting injury. Copper, in particular, has been implicated in generating reactive oxygen species, which can cause cell damage.

One way of studying the role of metals in the process is by sopping up the metal ions with molecules called chelators and then seeing what happens when the metal ions are out of the picture. When other scientists have done this they've found that chelators, by removing metals, hamper both amyloid beta clumping and the production of those harmful reactive oxygen species, suggesting that chelators could be useful in treating Alzheimer's disease.

However, most known chelators can't cross the blood-brain barrier, the barricade of cells that separates brain tissue from circulating blood, protecting the brain from harmful substances in the bloodstream. What's more, most chelators aren't precise enough to target only the metal ions in amyloid-beta; they're just as likely to grab and disable metals performing vital roles in other biological systems.

Lim and coworkers used a new strategy to develop "bi-functional" small molecules that not only grab metal ions, but also interact with amyloid-beta.

"The idea is simple," said Lim, who has joint appointments in the Department of Chemistry and the Life Sciences Institute. "We found molecules known for amyloid-beta recognition and then attached metal binding sites to them." In collaboration with Ayyalusamy Ramamoorthy, professor of chemistry and associate professor of biophysics, Lim then used NMR spectroscopy to confirm that the new, hybrid molecules still interacted with amyloid-beta.

In experiments in solutions with or without living cells, the researchers showed that the bi-functional molecules were able to regulate copper-induced amyloid-beta aggregation, not only disrupting the formation of clumps, but also breaking up clumps that already had formed. In fact, their molecules performed better than clioquinol, a clinically-available metal chelator that showed promise in early trials with Alzheimer's patients, but has side effects that limit its long-term use.

"Based on their small size and other properties, we believe our compounds will be able to cross the blood-brain barrier, but we want to confirm that using mouse models," Lim said. The researchers also plan experiments to see if their new chelators are as good at preventing and breaking up amyloid-beta plaques in the brains of mice as they are in solutions and cultured cells.

###

In addition to Lim and Ramamoorthy, coauthors include postdoctoral fellow Sarmad Hindo, graduate students Allana Mancino and Joseph Braymer, lab technician Yihong Liu, and NMR specialist Subramanian Vivekanandan.

The research was supported by U-M and the National Institutes of Health.

For more information:

Mi Hee Lim---http://www.lsi.umich.edu/facultyresearch/labs/lim and https://www.chem.lsa.umich.edu/chem/faculty/facultyDetail.php?Uniqname=mhlim

Ayyalusamy Ramamoorthy---http://www.ns.umich.edu/htdocs/public/experts/ExpDisplay.php?beginswith=Ramamoorthy

Journal of the American Chemical Society---http://pubs.acs.org/journal/jacsat

---
Contact: Nancy Ross-Flanigan
rossflan@umich.edu
734-647-1853
University of Michigan

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underBrainNeurology

Keep reading

Neurology

Neurologist Develops New Educational Tool

With a new application developed by a U-M neurologist, better understanding of the anatomy of the peripheral nervous system can be found right on your iPhone. Nerve Whiz is a free application for medical…

2 min read

Brain

A better way to remember

Scientists and educators alike have long known that cramming is not an effective way to remember things. With their latest findings, researchers at the RIKEN Brain Science Institute in Japan, studying eye movement…

3 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.